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ABSTRACT
Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats
Natalie R. Bruner
Kava-kava is a widely available and used herbal medicine that is not regulated in many
countries, including the United States. There are many questions concerning kava-kava’s
stimulus properties, potential for therapeutic use, and potential for abuse. Although there is
evidence that kava may possess some anxiolytic properties, the supplement’s mechanism of
action and the extent to which it may serve as an alternative to pharmaceutical anxiolytics are
unknown. To date, there is no research examining whether kava shares discriminative-stimulus
properties with a standard pharmaceutical anxiolytic such as chlordiazepoxide (CDP). The
current study compared different doses of kava in two groups of rats trained to discriminate
either a high or low training dose of CDP (i.p.). In order to assess time-course effects of kava
(p.o.), two tests were conducted per session at 60 (Test One) and 90 (Test Two) min following
administration of kava, CDP, or d-amphetamine. Dose-dependent substitution of CDP was found
in both training groups. d-Amphetamine did not substitute for either group at Test One, but
marginal substitution was found in both groups at the lower doses of d-amphetamine during Test
Two. Kava (560 mg/kg) occasioned responding indicative of partial substitution in both groups
during Test One and only the low-dose group during Test Two. Several procedural variables that
may have influenced the present results are discussed.
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1
Discriminative-stimulus and time-course effects of kava-kava in rats
For hundreds of years, the people of the South Pacific have consumed the beverage kavakava (kava) for ceremonial, medicinal and social purposes (Singh, 1992). The importance of
kava in the life of the South Pacific islanders is analogous to the use of alcohol in other cultures.
Cultivated from the tropical shrub Piper methysticum (meaning “intoxicating pepper”), the
traditional preparation consists of grinding down the thick kava root into an intoxicating murky
beverage. Consuming the beverage induces a relaxed state and can help to improve social
interaction (Stolerman, 1993). Kava has also been traditionally used as a natural anti-anxiety or
sedative medicine.
It was not until the 1990’s that kava gained significant attention as an herbal alternative
to pharmaceutical drugs for treatment of stress, anxiety, and pain. By 1994, kava had become
one of the top eight herbal remedies in the $18 million herbal remedy industry (O’Sullivan &
Lum, 2004). In 2002, several European countries banned the sales of the herb due to cases of
severe hepatic toxicity in users of kava. Because it is classified as an herbal supplement, the
Food and Drug Administration (FDA) of the United States does not regulate the quality of nor
approve preparations of kava prior to its marketing. However, following the European ban on
kava in 2002, the FDA did issue a consumer advisory pertaining to the potential harmful effects
of the herb. Subsequently, several herbal remedy retailers voluntarily withdrew kava-containing
items from their stores (O’Sullivan & Lum, 2004). The potential toxic effects as well as the
potential benefits of kava must be more closely examined to properly assess its usefulness as an
herbal medicine.
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Literature Review
Kava-kava’s active pharmacological agents consist of 18 compounds called kavalactones.
Six of these kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin,
and desmethysticin) account for about 95% of the kava extract (Ganzera & Khan, 1999). Smith
et al. (2001) found that of the six major kavalactones tested individually in a chick social
separation-stress paradigm, only dihydrokavain resulted in behavioral effects similar to those
following administration of the benzodiazepine chlordiazepoxide (CDP). Feltenstein et al. (2003)
reported that kava fractions containing the highest doses of dihydrokavain moderately
suppressed both distress vocalizations and stress-induced analgesia. These studies suggest that
some properties of kava may be similar to those of established anxiolytic drugs. More research is
needed to determine whether these shared stimulus properties of kava extract are mediated by the
total kavalactone content or from particular kavalactones.
Kavalactones appear to interact with GABAA receptors (Jussofie, Schmiz, & Heimke,
1994; Singh, 2005). These are the same receptor sites that anti-anxiety drugs such as
chlordiazepoxide and diazepam act upon. If kava affects the same receptors as these
benzodiazepines, it may be expected to have shared stimulus properties and anxiolytic effects.
Research investigating the use of kava in human participants supports kava as an
effective treatment for anxiety. Geier & Konstantinowicz (2004) used the Hamilton Anxiety
Scale as a primary dependent variable to assess self-rated subjective level of anxiety before and
after kava treatment. It was found that patients had a therapeutically relevant reduction in anxiety
in the kava-extract group compared to the placebo-control group. Another study with human
participants supports the finding that kava is beneficial for treating anxiety symptoms in anxiety
patients terminating treatment with benzodiazepines (Malsch & Kieser, 2001). This suggests that
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kava may be an effective substitute for pharmaceutical anxiolytics such as benzodiazepines.
Ernst (2006) conducted a systematic review of controlled clinical trials summarizing the
anxiolytic efficacy of herbal medicines. It was reported that kava is the only herbal medicine that
has been shown to have anxiolytic effects in humans.
The data concerning kava using animal models of anxiety is limited. Garrett, Basmadjian,
Khan, Schaneberg, and Seale (2003) found that kava extract significantly increased changes in
behavior, in a manner similar to that of drugs established as anxiolytics in humans, in two animal
models of anxiety. In the mirrored-chamber avoidance paradigm, a mouse entering the mirrored
chamber is surrounded by its own reflection on six sides. In the elevated-plus maze paradigm,
Plexiglas surrounds the arms of one runway of the maze, and the arms of the other runway are
open. Animal subjects in these assays typically spend less time in the mirrored chamber or open
arms of the elevated-plus maze relative to time spent in the enclosed runway leading into the
mirrored chamber or closed arms of the maze. However, following administration of a
benzodiazepine, time spent in the mirrored chamber or open arms of the maze is increased.
Administration of kava in these animal models of anxiety results in behavioral effects similar to
those following administration of benzodiazepines. Kava extract injected intraperitoneally (i.p.)
reduced both latency to enter and increased time spent in both the mirrored chamber of the
mirrored-chamber avoidance assay and the open arms of the elevated-plus maze assay, compared
to administration of vehicle. Rex, Morgenstern, & Fink (2002) used an elevated-plus maze to
determine orally administered (p.o.) kava-induced effects on time spent in the open arms of the
maze compared to the standard anxiolytic diazepam. They reported that kava extract (120-240
mg/kg) and diazepam (15 mg/kg) significantly affected the time spent in the open arms and
open-arm visits. Smith et al. (2001) used the chick social separation-stress paradigm to assess the
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behavioral effects of i.p. administered kava extract and isolated kavalactones. They found that
kava extract (30 mg/kg) and the kavalactone dihydrokavain (30 mg/kg) resulted in responses
comparable to that following administration of the “gold standard” anxiolytic CDP (5 mg/kg,
i.p.).
Positive results in three experimental paradigms across three species of animals suggest
that kava has effects on behavior similar to those produced by drugs classified as anxiolytics in
clinical settings with humans. To date, there are no studies examining the discriminativestimulus properties of kava in animals. The discriminative-stimulus properties of drugs may be
evaluated in a drug-discrimination procedure. The proposed study will determine if kava shares
discriminative-stimulus properties similar to those of CDP using rats as subjects.
The subjective effects of drugs may be trained to serve as discriminative stimuli using a
drug-discrimination procedure. In such a procedure, a discrimination is trained between a
specific dose of a drug and its vehicle (e.g., saline). In drug-discrimination training, one activity
(i.e., pressing a lever) is reinforced after drug administration and another activity (i.e., pressing a
second lever) is reinforced in the absence of the drug (i.e., after vehicle administration). If
differential responding is observed in drug-appropriate lever-pressing vs. non-drug or vehicleappropriate lever-pressing, then it may be concluded that the drug’s effects are acting as a
discriminative-stimulus (Branch, 1991). A common dosing schedule for drug (D) and vehicle (V)
in a two-week period (Monday-Friday) is VDVDD DVDVV. For drug days, one set of
contingencies is in effect (i.e., reinforcement available on the drug-appropriate lever). On vehicle
(non-drug) days, a second set of contingencies is in effect (i.e., reinforcement available on the
vehicle-appropriate lever).
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The drug-discrimination procedure may be used to ascertain whether another test drug
shares discriminative-stimulus properties with the training drug. A discrimination between the
training drug and vehicle is generally considered established when there is at least 80% correct
responding on the drug-appropriate lever following administration of the training drug.
Following drug training, another dose of the training drug or other drugs may be administered
prior to a test session. Drugs within the same pharmacological class and novel compounds are
often substituted to assess the extent to which the test drug may substitute for the training drug.
To establish that responding on the drug-appropriate lever indicates shared discriminativestimulus properties with the training drug and is not an artifact of general administration of a
drug, a negative control (usually a drug from another pharmacological class) is often included in
testing.
Stimulus generalization may be assessed using either quantal or graded measures.
Quantal indices characterize discriminative responses as all-or-none. They are measured using
nominal scales and are usually averaged across subjects (Stolerman, 1993). Graded indices may
allow for partial substitution of the test drugs and may be measured within and across subjects.
In a graded index, the proportion of responses corresponding to one of the options (i.e.,
percentage of total responses on drug-appropriate lever) may be used for data analysis. To ensure
that reinforcement is not serving a discriminative function, data analysis of test sessions are
based on responses made prior to reinforcer delivery, or discrimination tests are conducted in
extinction. Full generalization to the training drug is usually defined as at least 80% responding
on the drug-appropriate lever, 21-79% as partial substitution, and less than or equal to 20% of
total responses is characterized as no substitution. A dose-response function with the test drug
may be compared to the dose-response function generated during the initial drug training in the
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form of a generalization gradient. Generalization gradients plot the extent to which the test drug
produces a dose-effect curve similar to that of the training drug.
There are several variables that may influence generalization gradients. The dose used for
the training drug to establish and maintain a discrimination influences sensitivity to the drug. A
relatively low training dose will generally result in greater sensitivity to test stimuli, and doseresponse curves will subsequently be shifted to the left. Discriminations with relatively high
doses are generally easier to establish (i.e., requires fewer training sessions), but may result in
less sensitivity to discriminative-stimulus properties of test stimuli than that based on lower
training doses. The schedule of reinforcement used in training is another important factor to
consider. A schedule such as a relatively small fixed-ratio (FR) is often utilized for its capacity to
engender strong stimulus control (Stolerman, 1993). Using this schedule, responses are usually
emitted on a lever as a single unit, resulting in data that are more quantal in nature. A schedule
such as a variable-interval (VI), which may result in responses distributed between the two
choices, may result in data that are more graded in nature. However, VI schedules are
characterized by a poorer capacity for engendering stimulus control. Tandem VI-FR schedules
combine the advantages of these two schedules: strong stimulus control as well as fostering
responding that may result in data that are graded in nature. Pharmacokinetics of the drug with
respect to time-course effects is another important variable affecting the generalization gradient.
The onset and duration of the drug’s action will influence the point in time in which a test drug
may share discriminative-stimulus properties with the training drug. Time-course effects of a
drug may be assessed by conducting multiple tests in extinction (i.e., one test is conducted 60
min post-administration, and a second test is conducted 90 min post-administration).
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Statement of the Problem
Kava-kava is a widely available and used herbal medicine that is not regulated in many
countries, including the United States. There are many questions concerning kava’s stimulus
properties, potential for therapeutic use, and potential for abuse. Although there is evidence that
kava may possess some anxiolytic properties, the extent to which it may serve as an alternative
to pharmaceutical anxiolytics and the supplement’s mechanism of action are unknown. To date,
there is no research examining whether kava shares discriminative-stimulus properties with a
standard pharmaceutical anxiolytic such as CDP. Shared discriminative-stimulus properties
would suggest that kava may share other properties of pharmaceutical anxiolytics such as the
mechanism of action or abuse potential. The current study compared different doses of kava in
two groups of rats trained to discriminate either a high or low training dose of CDP. A positive
control (multiple doses of CDP) and negative control (the stimulant d-amphetamine) was also
incorporated in testing. Two generalization tests were conducted within each test session (Test
One at 60 min and Test Two at 90 min post-administration) to assess time-course effects of the
herb.
Method
Subjects
Sixteen experimentally naïve male Sprague-Dawley rats were used as subjects, and were
approximately two months of age at the start of the experiment. Rats were housed individually
with free access to water in their home cages. Temperature and humidity were maintained at
constant levels and there was a reversed 12-hour light-dark cycle in effect. All sessions were
conducted during the dark phase of the light-dark cycle. The subjects were fed approximately 15
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g of food one half hour following each experimental session. This schedule resulted in
approximately 22 hours of food deprivation prior to the start of each session.
Apparatus
Experimental sessions were conducted in eight standard operant-conditioning chambers
for rats, each enclosed in a melamine sound-attenuating cubicle (Med Associates, VT). Each
chamber contained a working area of 30.5 cm by 24.5 cm by 21.0 cm, a grid floor, and a 45-mg
pellet dispenser with a pellet receptacle centered between two retractable response levers. The
levers were 11.5 cm apart from each other and required at least a force 0.25 N for a response to
be recorded. The levers were 4.8 cm wide, protruded 1.9 cm into the chamber, and were elevated
8 cm from the grid floor. Two 28-V stimulus lights that were 2.5 cm in diameter were
approximately 7 cm above each lever. Each chamber contained a 28-V houselight on the wall
opposite to wall containing the operandum. A ventilation fan circulated air and served to mask
extraneous noise. Equipment was interfaced to a computer and experimental sessions and data
collection was programmed and conducted with MedPC-IV (Med Associates, VT).
Procedure
Initial Training. Training sessions were conducted five days a week (Monday through
Friday) at approximately the same time each day. The subjects were trained to lever press using a
free-operant acquisition procedure (cf: van Haaren, 1992; Anderson & van Haaren, 1999). Each
rat was placed in a darkened experimental chamber and the ventilation fan was turned on. Ten
min later, the houselight and stimulus lights above both levers were illuminated. Food was
delivered according to a conjoint FR 1 variable-time (VT) 60-s schedule. Values for the VT were
obtained using a Fleshler-Hoffman sequence generator (Fleshler-Hoffman, 1962). Rats received
one food pellet either after a lever press or after an average of 60 s has elapsed. If any subjects
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failed to acquire the response following the lever-press training procedure, the lever-press was
shaped through reinforcement of successive approximations. When subjects were obtaining most
food pellets via the lever press, subjects then completed an FR 1 schedule that alternated between
the left and right levers after the delivery of five food pellets on each lever for 40 food pellets
total. The ratio was increased gradually over consecutive sessions until an FR 10 was reached.
The next phase of lever press acquisition training consisted of a VI 15-s schedule. After
responding reliably on the VI 15-s schedule, subjects were then exposed to a VI 30-s schedule.
The subjects entered the next phase of the experiment after responding reliably on a VI 30-s
schedule.
Discrimination training. The subjects were divided into two groups of eight rats. Sessions
were conducted five, and then seven days a week. Initially, training began with a relatively low
training dose of CDP (3.0 mg/kg) for one group. The other group was exposed to a higher
training dose of CDP (17.0 mg/kg). The training doses were subsequently adjusted in order to
facilitate discrimination (i.e., the low training dose was increased to CDP 5.6 mg/kg), or to
decrease response suppression (i.e., the high training dose was decreased to CDP 13.0 mg/kg).
One of the subjects in the high-dose training group was changed to the lower training dose after
failing to respond following drug administration. The drug (D) or saline vehicle (V) was
administered via i.p. injection prior to each daily session in the following order for each twoweek period (Monday-Friday): VDVDD DVDVV. Following the injection, the subject was
placed immediately in the darkened experimental chamber and the ventilation fan was turned on.
After a period of 15 min, the houselight and both lever lights were illuminated, and both levers
were extended into the chamber. Food pellet presentation followed responses on the vehicle- or
drug-appropriate lever according to a tandem VI 30-s FR 10 (TAND (VI 30-s, FR 10)) schedule
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of reinforcement. For one half of each group, fulfilling the required responses on the left lever
resulted in food pellet delivery following injection of saline, and responses on the right lever
resulted in food pellet delivery following injection of CDP. For the other half of each group, the
levers were counterbalanced such that reinforced responses were on the left lever following CDP
injection and the right lever following saline injection. Responses on the other lever were
counted but had no other scheduled consequences (extinction; incorrect lever). Sessions were
terminated following the presentation of 40 food pellets or 30 min, whichever occurred first.
After 150 sessions, only one subject had met the original training criteria. Therefore, the dosing
schedule was slightly modified to constitute a 24-day period (seven days a week):
VDVDDDVDVDVV DVDVVVDVDVDD. In addition, the VI component of the training
schedule was removed, and for the rest of the experiment an FR 10 schedule of reinforcement
was in effect.
Generalization testing. Generalization testing began after the subjects emitted at least
80% correct lever presses before the delivery of the first food pellet for five consecutive sessions.
Rats that did not successfully complete discrimination training were not included in the testing
phase (i.e., three rats in the low-dose group). Generalization tests were conducted on Tuesdays
and Fridays, once following a vehicle injection session and once following a drug injection
session. Each dose of CDP, kava, and d-amphetamine was tested at least twice. The subjects
were injected (i.p.) and immediately placed in the darkened experimental chamber. After 15 min,
Test One began. Both levers were extended into the chamber and the houselight and both lever
lights were illuminated for five min or until completion of the response requirement for FR 10.
After completing the required responses, instead of delivery of a food pellet, both levers were
retracted, and the houselight and stimulus lights were darkened until the beginning of Test Two.
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During the interval between tests, all lights remained extinguished and the levers remained
retracted from the chamber. If the response requirement was not met within five min of the onset
of the test, the experimental chamber was darkened and the levers were retracted until Test Two
began. Thirty min following drug injection, a second generalization test commenced. This test
was identical to the first and the session was terminated upon its completion. Some
generalization tests were conducted using an i.p. route of administration for chlordiazepoxide,
saline, kava extract, and kava vehicle (see Drugs for vehicle composition).
After several generalization tests following i.p. administration of kava, it was evident that
kava was not generalizing to the training stimuli, so these data are not presented. In order to rule
out drug absorption issues due to poor solubility of the compound, a change was made. All drugs
were administered orally via gastric gavage (p.o.) on test days. Subjects were administered test
drugs 60 min prior to the start of Test One and placed back into their home cage. Forty-five min
following drug administration, subjects were placed into the operant-conditioning chamber and
the ventilation fan was turned on. Fifteen min later, Test One began. Test Two began 90 min
after drug administration. Contingencies during each test were the same as described above.
Generalization tests were conducted for CDP (1.0-13.0 mg/kg), d-amphetamine (0.3-3.0 mg/kg),
saline, kava vehicle, and kava extract (300-560 mg/kg). Most subjects received at least two
determinations of each dose. However, due to time constraints, some subjects experienced doses
of kava or d-amphetamine only once. In some instances, drug doses (e.g., kava 560 mg/kg, damphetamine 3.0 mg/kg) suppressed responding almost completely. The data from these
determinations are excluded from data analyses.
Drugs. Chlordiazepoxide hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in
0.9% saline vehicle and administered 15 min prior to training (i.p.) and 60 min prior to testing

12
(p.o.). Kava extract was generously supplied by the National Center for Natural Products
Research at the University of Mississippi (Oxford, MS). The extract was dissolved in the kava
vehicle (91% distilled water, 4% ethanol, 4% Tween 80, and 1% dimethyl sulfoxide) and
administered 60 min prior to testing (p.o.). Kavalactones comprised 84% of the kava extract. The
kavalactone content was comprised of 49% kavain, 18.6% dihydrokavain, 9.8% methysticin,
8.4% dihydromethysticin, 5.8% yangonin, and 4.8% desmethoxyangonin. d-Amphetamine
(Sigma-Aldrich Company, St. Louis, MO) was dissolved in 0.9% saline and administered 60 min
prior to testing (p.o.).
Data analysis. The percentage of correct (injection-appropriate) lever presses in training
was determined by dividing the number of responses made on the injection-appropriate lever by
the number of total responses made on both levers preceding the delivery of the first food pellet.
Response rate (responses per min) on the injection-appropriate lever in training was determined
by dividing the total number of lever presses on the injection-appropriate lever by the duration
(min) of each session. Training data were represented graphically in which the percent choice of
injection-appropriate lever was plotted as a function of injection type (drug or saline).
Calculations were the same for the generalization tests, except data collection ended
when the required responses were made or when the session timed out. Only data following oral
administration of the test drugs are presented. In testing, only percentage of total responses and
response rate on the CDP-appropriate were calculated and plotted. Test data were not included if
subjects failed to fulfill the schedule requirement (i.e., ten responses were not emitted on a single
lever). In the case where partial substitution of a test compound was found, the percentage of
total responses emitted on the CDP-appropriate lever was tested for significance with a 3-way
repeated measures ANOVA. Occasionally, subjects did not receive a test dose or failed to
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respond following a test dose. In these cases, data were interpolated from the group mean for that
dose. In the case that main effects (training group, test time, drug dose) were found, t-tests were
conducted as post-hoc analyses. The median effective dose (ED50) for each drug was calculated
by log-linear interpolation of the descending portion of the dose-effect curve. For all statistical
tests, p < 0.05 was considered to be significant. The percentage of responses emitted greater than
or equal to 80% on the CDP lever was considered to be full substitution, 21-79% partial
substitution, and less than or equal to 20% no substitution.
Results
Discrimination Training. The CDP discrimination required an average of 40 training
sessions on FR 10 for the low-dose group (range 25-62 sessions) and an average of 32 sessions
(range 23-49 sessions) for the high-dose group. For the last ten sessions of the training phase, the
mean percent correct lever responding was 93.7% (range 86.6-100%) for the low-dose training
group and 95.9% (range 88.6-100%) for the high-dose training group. The mean response rate on
the stimulus-appropriate lever was 64.5 rsp/min (range 56.6-82.0 rsp/min) and 62.3 rsp/min
(range 52.9-73.4 rsp/min) for the low-dose and high-dose group, respectively. Subsequent t-tests
revealed no significant differences between groups for mean percentage of total responses or
response rate on the stimulus-appropriate lever.
Generalization of CDP. In general, full substitution of CDP was found at doses
equivalent to and above that of the training dose for both groups in Test One (Figure 1). In both
groups, doses smaller than the training dose only partially substituted for the training dose. The
percentage of total responses emitted on the CDP-appropriate lever was functionally related to
the dose of CDP administered. The lower ED50 value in the low-dose group (especially in Test
One) suggests greater sensitivity to the discriminative-stimulus effects of CDP administration.

14
During Test One, the ED50s for the low-dose and high-dose groups were CDP 2.9 mg/kg and
CDP 5.9 mg/kg, respectively. However, subsequent t-tests did not reveal any significant
differences in ED50 values between groups. Individual data during Test One following
administration (p.o.) of CDP are presented in Table 1.
On average, full substitution of the training dose was found in the high-dose group, but
only partial substitution was found in the low-dose group during Test Two (Figure 1). Three of
the rats in the low- training group and only one in the high-dose group emitted at least 80% of
total responses on the CDP lever during Test Two following administration of the training dose.
In both groups, the average percentage of total responses emitted on the CDP-appropriate lever
was functionally related to CDP dose, such that the average percentage increased as the dose size
increased. The ED50s for the low-dose and high-dose groups were CDP 3.5 mg/kg and CDP 3.3
mg/kg, respectively. Subsequent t-tests did not reveal any significant differences in ED50 values
between subjects. Individual data during Test Two following CDP administration are presented
in Table 2.
Response rates on the CDP-appropriate lever were also calculated during both tests. For
both groups, the mean response rate on the CDP-appropriate lever was functionally related to the
dose of CDP administered (Figure 2) during Test One. The response rate on the CDP-appropriate
lever systematically increased as the dose of CDP increased. During Test One, the average
response rate on the CDP-appropriate lever for the low-dose group (52.9 rsp/min) was lower than
that of the high-dose group (77.2 rsp/min) following administration of the training dose.
Individual data for response rate on the CDP-appropriate lever in Test One are presented in
Table 5.

Table 1
Mean Percent Responding, S.E.M, and Number of Determinations for Each dose (SEM, determinations) on CDP-appropriate Lever
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test One

Training

Test One

Rat ID

Dose

CDP 1.0

CDP 3.0

CDP 5.6

CDP 10.0

CDP 13.0

S60-2

Low (5.6)

71.1 (9.7, 3)

9.1 (0.0, 2)

75.0 (22.1, 4)

-

-

S60-4

Low (5.6)

4.5 (4.5, 2)

44.0 (27.4, 2)

87.1 (3.8, 2)

95.5 (4.5, 2)

-

S60-5

Low (5.6)

0.0 (0.0, 2)

96.9 (3.0, 3)

95.5 (4.5, 2)

-

-

S60-8

Low (5.6)

16.7 (16.7, 2)

91.7 (8.3, 2)

100.0 (0.0, 2)

100.0 (0.0, 2)

-

S70-5

Low (5.6)

33.3 (33.3, 3)

50.0 (50.0, 2)

100.0 (0.0, 2)

100.0 (0.0, 1)

-

S70-7

Low (5.6)

11.5 (11.5, 2)

66.7 (33.3, 3)

89.3 (6.7, 3)

100.0 (0.0, 1)

-

27.3 (9.8)

62.9 (11.8)

88.9 (6.0)

98.5 (1.5)

-

Group mean

S70-3

High (13.0)

33.3 (33.3, 3)

0.0 (0.0, 2)

33.3 (33.3, 3)

-

100.0 (100.0, 3)

S70-4

High (13.0)

-

0.0 (0.0, 2)

4.5 (4.5, 2)

-

81.4 (9.5, 3)

S60-7

High (13.0)

0.0 (0.0, 1)

27.3 (24.3, 4)

100.0 (0.0, 2)

-

100.0 (0.0, 3)

25.0 (25.0)

13.6 (12.4)

44.2 (19.8)

-

93.8 (4.1)

Group mean
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Table 2
Mean Percent Responding, S.E.M, and Number of Determinations for Each dose (SEM, determinations) on CDP-appropriate Lever
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test Two
Training

Test Two

Rat ID

Dose

CDP 1.0

CDP 3.0

CDP 5.6

CDP 10.0

CDP 13.0

S60-2

Low (5.6)

50.5 (24.8, 3)

26.8 (17.7, 2)

55.0 (26.0, 4)

-

-

S60-4

Low (5.6)

0.0 (0.0, 2)

62.5 (19.7, 2)

100.0 (0.0, 2)

37.9 (14.8, 2)

-

S60-5

Low (5.6)

57.0 (33.9, 2)

69.7 (30.3, 3)

100.0 (0.0, 2)

-

-

S60-8

Low (5.6)

0.0 (0.0,2)

0.0 (0.0,2)

100.0 (0.0, 2)

68.8 (31.2, 2)

-

S70-5

Low (5.6)

66.7 (33.3, 3)

50.0 (50.0, 2)

100.0 (0.0, 2)

100.0 (0.0, 1)

-

S70-7

Low (5.6)

35.7 (35.7, 2)

64.1 (27.9, 3)

57.1 (29.7, 3)

100.0 (0.0, 1)

-

38.4 (11.6)

45.8 (11.6)

67.0 (11.7)

68.9 (14.4)

-

Group mean

S70-3

High (13.0)

0.0 (0.0, 3)

100.0 (0.0, 2)

72.2 (27.8, 3)

-

100.0 (0.0, 3)

S70-4

High (13.0)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

-

71.3 (24.2, 3)

S60-7

High (13.0)

9.1 (0.0, 1)

0.0 (0.0, 4)

100.0, (0.0, 2)

-

69.7 (30.3, 3)

2.3 (2.3)

25.0 (16.4)

59.5 (19.2)

-

80.3 (12.2)

Group mean
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Table 3
Mean Percent Responding, S.E.M, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever
Following d-Amphetamine Administration (mg/kg, p.o.) in Individual Subjects

Training
Rat ID

Dose

Test One

Test Two

Saline

d-amp 0.3

d-amp 1.0

d-amp 3.0

Saline

d-amp 0.3

d-amp 1.0

d-amp 3.0

S60-2

Low (5.6)

18.0 (3.3, 4)

16.7 (0.0, 1)

9.1 (0.0, 1)

-

6.4 (4.0, 4)

0.0 (0.0, 1)

55.6 (0.0, 1)

-

S60-4

Low (5.6)

0.0 (0.0, 5)

-

8.3 (8.3, 2)

11.1 (11.1, 2)

31.8 (20.5, 5)

-

8.3 (8.3, 2)

0.0 (0.0, 2)

S60-5

Low (5.6)

2.3 (2.3, 4)

0.0 (0.0, 3)

0.0 (0.0, 3)

-

2.3 (2.3, 4)

31.9 (18.1, 3)

30.3 (30.3, 3)

-

S60-8

Low (5.6)

0.0 (0.0, 3)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 3)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

S70-5

Low (5.6)

0.0 (0.0, 2)

0.0 (0.0, 3)

-

50.0 (50.0, 2)

30.3 (30.3, 3)

0.0 (0.0, 2)

-

S70-7

Low (5.6)

0.0 (0.0, 4)

-

9.4 (9.4, 4)

69.8 (4.6, 4)

55.6 (27.8, 3)

-

Group mean

23.8 (23.8, 4) 43.1 (21.6, 3)

3.7 (1.6)

16.3 (9.9)

11.9 (6.6)

6.7 (6.7)

13.8 (6.1)

42.4 (11.0)

25.4 (10.5)

0.0 (0.0)

S70-3

High (13.0)

0.0 (0.0, 3)

0.0 (0.0, 3)

0.0 (0.0, 2)

-

0.0 (0.0, 3)

38.9 (30.9, 3)

0.0 (0.0, 2)

-

S70-4

High (13.0)

0.0 (0.0, 4)

0.0 (0.0, 2)

0.0 (0.0, 2)

-

12.6 (8.4, 4)

18.8 (9.7, 2)

0.0 (0.0, 2)

-

S60-7

High (13.0)

0.0 (0.0, 4)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 4)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

3.4 (2.6)

30.9 (17.9)

0.0 (0.0)

0.0 (0.0)

Group mean
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Table 4
Mean Percent Responding, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever
Following Kava Administration (mg/kg, p.o.) in Individual Subjects

Training

Test One

Test Two

Rat ID

Dose

kava vehicle

kava 300

kava 560

kava vehicle

kava 300

kava 560

S60-2

Low (5.6)

23.1 (0.0, 1)

23.1 (0.0, 1)

33.9 (24.9, 2)

9.1 (0.0, 1)

9.1 (0.0, 1)

54.5 (45.5, 2)

S60-4

Low (5.6)

4.5 (2.5, 2)

0.0 (0.0, 2)

33.3 (28.9, 3)

4.5 (4.5, 2)

19.9 (3.2, 2)

8.6 (4.8, 3)

S60-5

Low (5.6)

33.3 (33.3, 3)

13.7 (13.7, 3)

95.5 (4.5, 2)

30.3 (30.3, 3)

24.8 (12.6, 3)

4.5 (4.5, 2)

S60-8

Low (5.6)

10.3 (10.3, 4)

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 4)

0.0 (0.0, 2)

0.0 (0.0, 2)

S70-5

Low (5.6)

0.0 (0.0, 1)

0.0 (0.0, 2)

0.0 (0.0, 3)

9.1 (0.0, 1)

8.3 (8.3, 2)

66.7 (33.3, 3)

S70-7

Low (5.6)

0.0 (0.0, 2)

0.0 (0.0, 2)

91.7 (18.3, 2)

0.0 (0.0, 2)

28.2 (5.1, 2)

69.0 (2.4, 2)

15.8 (9.3)

5.4 (3.8)

38.7 (12.0)

7.8 (3.8)

17.7 (7.4)

34.4 (11.4)

Group mean
High (13.0)

0.0 (0.0, 2)

0.0 (0.0, 3)

0.0 (0.0, 3)

0.0 (0.0, 2)

5.6 (5.6, 3)

9.5 (9.5, 3)

S70-3

High (13.0)

0.0 (0.0, 1)

4.5 (4.5, 3)

30.3 (30.3, 1)

0.0 (0.0, 1)

33.3 (33.3, 3)

0.0 (0.0, 1)

S70-4

High (13.0)

0.0 (0.0, 1)

11.1 (11.1, 2)

42.9 (29.7, 3)

0.0 (0.0, 1)

0.0 (0.0, 2)

30.3 (30.3, 3)

0.0 (0.0)

5.3 (4.2)

31.4 (17.0)

0.0 (0.0)

14.6 (12.4)

17.1 (12.9)

Group mean

18

S60-7

Table 5
Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test One
Training

Test One

Rat ID

Dose

CDP 1.0

CDP 3.0

CDP 5.6

CDP 10.0

CDP 13.0

S60-2

Low (5.6)

34.4 (10.2, 3)

4.3 (0.3, 2)

48.4 (15.4, 4)

-

-

S60-4

Low (5.6)

2.8 (2.8, 2)

18.7 (8.7, 2)

66.0 (19.8, 2)

76.2 (9.5, 2)

-

S60-5

Low (5.6)

0.0 (0.0,2)

44.8 (8.3, 3)

38.1 (8.1, 2)

-

-

S60-8

Low (5.6)

11.6 (11.6, 2)

59.7 (40.3, 2)

75 (0.0, 2)

85 (35.0, 2)

-

S70-5

Low (5.6)

13.3 (13.3, 3)

16.7 (16.7, 2)

70.2 (15.6, 2)

100.0 (0.0, 1)

-

S70-7

Low (5.6)

3.8 (3.8, 2)

25.9 (13.6, 3)

33.7 (8.2, 3)

50.0 (0.0, 1)

-

12.8 (4.7)

29.4 (7.4)

52.9 (6.2)

78.8 (11.5)

-

Group mean

High (13.0)

37.5 (37.5, 3)

0.0 (0.0,2)

20 (39.2, 3)

-

19.2 (3.4, 3)

S70-4

High (13.0)

-

0.0 (0.0,2)

5.0 (5.0, 2)

-

75.8 (34.7, 3)

S60-7

High (13.0)

0.0 (0.0, 1)

28.0 (24.2, 4)

85.7 (0.0, 2)

-

106.7 (6.7, 3)

18.8 (18.8)

14.0 (12.4)

34.5 (15.5)

-

77.2 (13.2)

19

S70-3

Group mean

Table 6
Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever
Following CDP Administration (mg/kg, p.o.) in Individual Subjects During Test One
Training

Test Two

Rat ID

Dose

CDP 1.0

CDP 3.0

CDP 5.6

CDP 10.0

CDP 13.0

S60-2

Low (5.6)

16.9 (10.4, 3)

11.4 (7.9, 2)

24.0 (12.0, 4)

-

-

S60-4

Low (5.6)

0.0 (0.0,2)

16.5 (12.1, 2)

44.9 (9.6, 2)

5.9 (0.3, 2)

-

S60-5

Low (5.6)

17.7 (13.9, 2)

16.5 (7.3, 3)

34.6 (3.0, 2)

-

-

S60-8

Low (5.6)

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 2)

31.0 (25.3, 2)

-

S70-5

Low (5.6)

29.3 (5.5, 3)

13.1 (13.1, 2)

42.6 (7.4, 2)

60.0 (0.0, 1)

-

S70-7

Low (5.6)

15.0 (15.0, 2)

18.5 (10.2, 3)

14.3 (8.3, 3)

18.2 (0.0, 1)

-

14.6 (4.2)

12.4 (3.3)

25.5 (5.2)

25.3 (10.6)

-

Group mean

S70-3

High (13.0)

0.0 (0.0,3)

30.0 (0.0, 2)

26.1 (12.9, 3)

-

40.5 (3.2, 3)

S70-4

High (13.0)

-

0.0 (0.0,2)

0.0 (0.0, 2)

-

25.6 (4.0, 3)

S60-7

High (13.0)

5.5 (0.0, 1)

21.4 (21.4, 4)

70.2 (15.6, 2)

-

28.8 (24.1, 3)

1.4 (1.4)

18.2 (10.8)

31.2 (12.5)

-

31.0 (7.5)

Group mean

20

Table 7
Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever
Following d-amphetamine Administration (mg/kg, p.o.) in Individual Subjects
Training

Test One

Test Two

Rat ID

Dose

Saline

d-amp 0.3

d-amp 1.0

d-amp 3.0

Saline

d-amp 0.3

d-amp 1.0

d-amp 3.0

S60-2

Low (5.6)

6.8 (1.4, 4)

1.8 (0.0, 1)

4.3 (0.0, 1)

-

0.1 (0.7, 4)

0.0 (0.0, 1)

25.0

-

S60-4

Low (5.6)

0.0 (0.0, 5)

-

2.9 (2.9, 2)

1.0 (1.0, 2)

10.2 (7.0, 5)

-

2.1 (2.1)

0.0 (0.0, 2)

S60-5

Low (5.6)

0.6 (0.6, 4)

0.0 (0.0, 3)

0.0 (0.0, 3)

-

0.4 (0.4, 4)

8.3 (5.5, 3)

3.0 (3.0)

-

S60-8

Low (5.6)

0.0 (0.0, 3)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 3)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

S70-5

Low (5.6)

0.0 (0.0, 2)

0.0 (0.0, 3)

0.0 (0.0, 2)

-

7.2 (7.2, 2)

8.7 (8.7, 3)

0.0 (0.0, 2)

-

S70-7

Low (5.6)

0.0 (0.0, 4)

14.4 (8.7, 4)

8.8 (6.8, 3)

-

1.6 (1.6, 4)

21.0 (3.8, 4)

17.9 (9.0)

-

1.3 (0.6)

5.4 (3.6)

2.8 (1.7)

0.6 (0.6)

3.5 (1.8)

12.3 (3.5)

7.1 (3.1)

0.0 (0.0)

Group mean
S70-3

High (13.0)

0.0 (0.0, 3)

0.0 (0.0, 3)

0.0 (0.0, 2)

-

0.0 (0.0, 3)

10.4 (9.1, 3)

0.0 (0.0, 2)

-

S70-4

High (13.0)

0.0 (0.0, 4)

0.0 (0.0, 2)

0.0 (0.0, 2)

-

0.0 (0.0, 4)

11.8 (4.3), 2

0.0 (0.0, 2)

-

S60-7

High (13.0)

0.0 (0.0, 4)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 4)

-

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

10.9 (5.2)

0.0 (0.0)

0.0 (0.0)

Group mean
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Table 8
Mean Responses per Minute, SEM, and Number of Determinations for Each Dose (SEM, determinations) on CDP-appropriate Lever
Following Kava Administration (mg/kg, p.o.) in Individual Subjects
Training

Test One

Test Two

Rat ID

Dose

kava vehicle

kava 300

kava 560

kava vehicle

kava 300

kava 560

S60-2

Low (5.6)

9.0 (0.0, 1)

6.0 (0.0, 1)

13.7 (9.4, 2)

2.1 (0.0, 1)

2.1 (0.0, 1)

30.7 (29.4, 2)

S60-4

Low (5.6)

2.5 (2.5, 2)

0.0 (0.0, 2)

16.4 (14.9, 3)

0.4 (0.4, 2)

1.3 (0.7, 2)

0.9 (0.6, 3)

S60-5

Low (5.6)

13.7 (13.7, 3)

1.6 (1.6, 3)

23.9 (7.7, 2)

11.4 (1.7, 3)

4.8 (4.8, 3)

0.7 (0.7, 2)

S60-8

Low (5.6)

2.9 (2.9, 4)

0.0 (0.0, 2)

0.0 (0.0, 2)

0.0 (0.0, 4)

0.0 (0.0, 2)

0.0 (0.0, 2)

S70-5

Low (5.6)

0.0 (0.0, 1)

0.0 (0.0, 2)

0.0 (0.0, 2)

1.3 (0.0, 1)

2.7 (2.7, 2)

23.9 (12.2, 3)

S70-7

Low (5.6)

0.0 (0.0, 2)

0.0 (0.0, 2)

33.0 (9.9, 3)

0.0 (0.0, 2)

7.8 (2.5, 2)

9.9 (0.8, 2)

4.4 (2.4)

0.9 (0.6)

13.6 (4.5)

2.2 (1.3)

3.3 (1.4)

11.2 (5.1)

Group mean
S60-7

High (13.0)

0.0 (0.0, 2)

0.0 (0.0, 3)

0.0 (0.0, 3)

0.0 (0.0, 2)

5.0 (5.0, 3)

4.0 (4.0, 3)

S70-3

High (13.0)

0.0 (0.0, 1)

0.0 (0.0, 2)

0.0 (0.0, 3)

0.0 (0.0, 1)

6.9 (6.9, 2)

0.0 (0.0, 3)

S70-4

High (13.0)

0.0 (0.0, 1)

10.0 (10.0, 3)

30.0 (17.3, 2)

0.0 (0.0, 1)

0.0 (0.0, 3)

22.2 (22.2, 2)

0.0 (0.0)

4.7 (3.7)

22.4 (11.4)

0.0 (0.0)

4.5 (3.0)

11.2 (9.4)

Group mean
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Average Percent of Total Responses on CDP-Appropriate Lever

Figure 1.
Low-dose group, Test One

High-dose group, Test One

Low-dose group, Test Two

High-dose group, Test Two

Drug Dose (mg/kg)
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Figure 1. Mean percent and SEM of total responses emitted on the CDP-appropriate lever for each of the test doses of CDP, dAmphetamine, kava, kava vehicle, and saline for the low-dose training group (left panels) and high-dose training group (right
panels) as a function of test dose. The top graphs reflect responding 60 min following administration of the test drug (Test One),
and the bottom graphs reflect responding 90 min post-administration (Test Two).

Average Response Rate (rsp/min) on CDP-Appropriate Lever

Figure 2.
Low-dose group, Test One

High-dose group, Test One

Low-dose group, Test Two

High-dose group, Test Two

Drug Dose (mg/kg)
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Figure 2. Mean response rate and SEM on the CDP-appropriate lever for each of the test doses of CDP, d-amphetamine, kava,
kava vehicle, and saline for the low dose training group (left panels) and high-dose training group (right panels) as a function of
test dose. The top graphs reflect responding 60 min following administration of the test drug (Test One), and the bottom graphs
reflect responding 90 min post-administration (Test Two).
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During Test Two, the average response rate on the CDP-appropriate lever was lower than that
found during Test One for both groups. As found in Test One, the average response rate for the
low-dose group (25.5 rsp/min) was lower than that found for the high-dose group (31.0 rsp/min).
In general, the response rate on the CDP-appropriate lever systematically decreased as a function
of dose for both groups. Group means and individual data for response rate on CDP-appropriate
lever in Test Two are presented in Figure 2 and Table 6, respectively.
Generalization of saline vehicle. The average percentage of total responses and response
rate on the CDP-appropriate lever during both tests following saline administration was also
calculated. Saline served as the vehicle for both CDP and negative control d-amphetamine. For
both groups, no substitution following saline administration was found in either test. Group
means and individual data for percent responding on the CDP-appropriate lever during Test One
are presented in Figure 1 and Table 2, respectively. Test Two group means (Figure 2) and
individual data (Table 6) for response rates on the CDP-appropriate lever following saline
administration are also presented.
Generalization of d-amphetamine (negative control). In general, evidence of substitution
of d-amphetamine was not found during Test One. However, partial substitution was found in
Test Two. The 3-way repeated measures ANOVA revealed a main effect of percentage of total
responses emitted on the CDP-appropriate lever for d-amphetamine of test time, F(1, 7) = 39.5, p
< 0.01, and group, F(1, 7) = 20.6, p = 0.05. No main effect was found for dose, F(2, 14) = 2.5, p
= 0.11. Because only three of nine subjects fulfilled the response requirement following
administration of d-amphetamine 3.0 mg/kg, these data were not included in the analyses.
Administration of negative control d-amphetamine (0.3-3.0 mg/kg) did not occasion
responding indicative of substitution during Test One in either group of rats (Figure 1). The low-
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dose group (6.7-16.3%) emitted a higher average percentage of responses more than the highdose group (0.0-0.0%) on the CDP-appropriate lever following administration of damphetamine. With the exception of one subject (S70-7), partial substitution of d-amphetamine
was not found in individual subjects (Table 3). The average response rate on the CDPappropriate lever in Test One was found to systematically increase as the dose of d-amphetamine
decreased in the low-dose group (Figure 2). The low-dose group (M = 17.6, SEM = 3.3) had a
higher average percentage of total responses on the CDP-appropriate lever following damphetamine administration than the high-dose group (M = 5.6, SEM = 2.8). Response rates on
the CDP-appropriate lever during Test One for individual subjects are presented in Table 7.
During Test Two, administration of the lower doses of d-amphetamine resulted in
responding on the CDP-appropriate lever indicative of partial substitution in both groups (Figure
1). As was found in Test One, the average percentage of responses and response rate on the
CDP-appropriate lever following d-amphetamine administration was slightly higher in the lowdose group (0.0-42.4%) than the high-dose group (0.0-30.9%). On average, the percentage of
total responses emitted on the CDP-appropriate lever following d-amphetamine administration
was significantly more during Test Two (M = 21.0, SEM = 4.2) than during Test One (M = 6.1,
SEM = 2.0). Individual data for average percentage of total responses on the CDP-appropriate
lever are presented in Table 1. The average percentage of total responses (Figure 1) and response
rate (Figure 2) on the CDP-appropriate lever systematically increased as the dose of damphetamine decreased. Response rates on the CDP-appropriate for individual subjects (Table 7)
during Test Two are presented.
Generalization of kava. In general, partial substitution of kava was found in both groups
at Test One, but only the low-dose group during Test Two. The percent of total responses
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emitted and response rate on the CDP-appropriate lever was functionally related to dose with an
average of 38.7% maximum substitution at any dose. The 3-way repeated measures ANOVA
revealed a significant main effect of kava dose, F(2, 14) = 6.1, p = .01 with average percentage
of total responses on the CDP-appropriate lever. No main effects were found for test time, F(1,
7) = .03, p = .86 or group, F(1, 7) = 1.76, p = .23.
Partial substitution of kava was found for kava 560 mg/kg in both groups during Test
One (Figure 1). Subjects emitted a significantly higher average percentage of total responses on
the CDP-appropriate lever following administration of kava 560 mg/kg (M = 10.1, SEM = 2.6)
than kava 300 mg/kg (M = 31.7, SEM = 7.6). A subsequent t-test revealed a significant
difference of percentage of total responses on the CDP-appropriate lever between kava vehicle
and kava 560 mg/kg (p < .05). The average percent responding on the CDP-appropriate lever
was slightly higher in the low-dose group (maximum 38.7 %) than the high-dose group
(maximum 31.4%). However, two rats in the low-dose group and one rat in the high-dose group
did not respond on the CDP-appropriate lever following administration of kava (Table 4). Partial
substitution was not found following administration of kava 300 mg/kg, except for one rat in the
low-dose group (S60-2). Following administration of kava, the response rate on the CDPappropriate lever was functionally related to dose. No substitution was found in either group
during Test One for kava vehicle. Group data for response rates on the CDP-appropriate lever are
presented in Figure 2. Response rates on the CDP-appropriate lever individual data are presented
in Table 8.
Partial substitution of kava was found during Test Two for kava 560 mg/kg in the lowdose group only (Figure 1). In this group, the average percentage of total responses and response
rate on the CDP-appropriate lever were slightly lower in Test Two than Test One following
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administration of kava 560 mg/kg. Following administration of kava, the response rate on the
CDP-appropriate lever was functionally related to dose in both groups. On average,
administration of kava 300 mg/kg did not result in partial substitution for either group. However,
two subjects in the low-dose group and one subject in the high-dose group did emit at least 20%
of the total responses on the CDP-appropriate lever. No substitution was observed following
administration of kava vehicle in either group during Test Two (Figure 1). Individual data for
percent responding (Table 4) and response rate (Table 8) on the CDP-appropriate lever during
Test Two following kava administration are presented.
Discussion
Dose-dependent substitution of CDP was found in both the low and high-dose training
groups. Although the low-dose group appeared to be more sensitive to the effects of CDP
because of the lower ED50 values, no significant differences were found between groups. The
negative control d-amphetamine did not substitute for CDP in either group during Test One.
However, during Test Two, marginal substitution was found in both groups at the lower doses of
d-amphetamine. Kava 560 mg/kg was found to occasion partial substitution in both groups
during Test One and only the low-dose group during Test Two.
Administration of kava 560 mg/kg resulted in partial substitution for the training dose of
CDP in both groups 60 min post-administration (Test One). Ninety min post-administration (Test
Two), partial substitution was observed in the low-dose group only. However, the extent to
which kava 560 mg/kg generalized to the training dose was modest (i.e., 31.4%–38.7%). For
some rats, full substitution was observed following administration of kava 560 mg/kg. Individual
differences in sensitivity to methods and drugs used in the present experiment may have
contributed to the variability in substitution observed. Several procedural variables may have
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influenced the present results. One potential variable that may have influenced the findings is
that the training doses of CDP may have engendered poor stimulus control for other potential
GABAA agonists like kava. Perhaps utilizing a shorter-acting benzodiazepine (e.g., midazolam)
for discrimination training may enhance stimulus control. It is possible that administration of
kava results in effects that are more sedative than anxiolytic (see discussion below). Therefore, it
may be worthwhile to investigate the discriminative-stimulus effects of kava in rats trained to
discriminate a short-acting barbiturate from saline.
Perhaps characteristics of the particular preparation of kava used in this study may have
influenced the present results. Kava dose-dependently increased the average percentage of total
responding on the CDP-appropriate lever to a range considered as partial substitution. At higher
doses, kava may fully substitute for CDP. It is possible that administration of kava had effects on
motivation (i.e., kava had anorexic effects). However, this is unlikely because subjects consumed
all of the daily food that was provided 30 min following completion of the session. Previous
research had indicated that particular kavalactones, particularly dihydrokavain, might mediate
effects similar to benzodiazepines in behavioral tests (e.g., Feltenstein et al, 2003). Perhaps the
preparation of kava extract used in this study did not have a high enough content of a particular
kavalactone to occasion full substitution. The samples used by Feltenstein et al. that resulted in
anxiolytic effects contained 15.0-67.5% dihydrokavain, while the sample used in this experiment
contained 18.6% dihydrokavain. Future work may test effects of different samples of kava
extract containing higher concentrations of different kavalactones. Another possibility would be
to examine effects of dihydrokavain or other kavalactones administered alone, instead of within
the kava extract. However, there is reason to believe that the extract was behaviorally active, as
subjects were visibly sedated and sometimes failed to respond following administration of kava
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560 mg/kg. Four subjects in the high-dose group died or had to be euthanized due to
gastrointestinal complications that may or may not have been related to kava administration. In
2002, the FDA issued a warning pertaining to the potential harmful effects of kava. It is possible
that the doses of kava used were having harmful effects on the subjects. Because of the potential
toxic effects of this drug, future research investigating kava’s use as an herbal medicine is
warranted.
Another variable that may have influenced the present results was the change in training
doses in both groups. In order to obtain a reliable discrimination between CDP and saline, a few
modifications were made to the procedure. Administration of CDP 3.0 mg/kg failed to generate
discriminated responding in the low-dose group. When the training dose was increased to 5.6
mg/kg and the response requirement was reduced to FR 10 (see discussion below), most subjects
acquired the discrimination. In the high-dose group, CDP 17.0 mg/kg suppressed responding
almost entirely. When the training dose was decreased to CDP 13.0 mg/kg, all subjects acquired
the discrimination and the average response rate was only slightly lower than that of the lowdose group.
In addition to modifying the training doses of CDP, the reinforcement schedule had to be
modified during training in order to facilitate discrimination. The VI component of the tandem
VI 30-s FR 10 was removed, and only an FR 10 schedule of reinforcement was in effect. As a
result, this resulted in data that were more quantal in nature, due to the all-or-none responding
that often occasion FR schedules of reinforcement (e.g., Stolerman, 1993).
Another variable that may have influenced the results of the present experiment is the
altered route of administration during testing. In order to test substitution of kava, drugs had to
be administered orally on test days. Although CDP was still administered i.p. on training days,
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using the p.o. route of administration on testing days did not seem to affect substitution of CDP.
The training doses of CDP administered orally engendered full substitution in both training-dose
groups. The subjective effects of the drugs appeared to be the same, regardless of route of
administration.
Interestingly, during Test Two the negative control d-amphetamine 0.3 mg/kg (in both
groups) and d-amphetamine 1.0 mg/kg (in the low-dose group) partially substituted for CDP.
However, the extent of the substitution was only marginal, and may have been due to effects of
extinction in Test One (i.e., no food received after fulfilling the response requirement during Test
One might occasion responding on opposite lever during Test Two). It may be useful to examine
sessions in which effects of different time courses are examined individually (e.g., Anderson and
van Haaren, 1999). These authors investigated the hypothesis that a drug’s time-course effects
may be evaluated within subjects and within a single session. Two generalization tests were
given following cocaine administration, one at 10 min and one at 30 min. However, the authors
found the effects of exposure to extinction in Test One on responding during Test Two to be
negligible. There were no differences in generalization gradients that were obtained 30 min after
cocaine administration, regardless of whether another gradient was obtained after a
generalization test was conducted 10 min post-administration. This may not have been the case
in the present study.
In conclusion, in the present study it was found that kava 560 mg/kg partially substituted
for the training stimuli in both the high- and low-dose training groups 60 min (both groups) and
90 min (low-dose group only) post-administration. At 60 min post-administration, kava 560
mg/kg shared some discriminative-stimulus effects with the training stimuli in both groups. It
appears as though in the high-dose group, the discriminative-stimulus effects of kava 560 mg/kg
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were diminishing 90 min post-administration. However, kava 560 mg/kg still partially
generalized to the training stimulus in the low-dose group 90 min after administration. At
present, it is unclear why kava failed to fully substitute for the training doses of CDP. Although
it is possible that administration of kava may not fully substitute for benzodiazepines, further
research is warranted to rule out other variables that may have influenced the present results.
Future research may incorporate a different benzodiazepine as a training drug to perhaps
engender stronger stimulus control. Another possibility that kava failed to fully substitute may be
due to the particular preparation of kava used in this study, or the chemical structure of kava
extract itself. In the case that kava acts more as a sedative than anxiolytic, it may generalize to a
different drug class (e.g., barbiturate). Future research should also examine the possibility that
extinction during Test One may have resulted in responding on the opposite lever during Test
Two by incorporating a phase in which subjects are presented with tests at different times.
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